文献速递咽喉与嗓音

犬环后杓肌注射长春新碱的毒性试验

Toxicity trial of canine posterior cricoarytenoid intramuscular vincristine injections.
PubMed 文献 · Laryngoscope · 2017-12-08

所有动物黏膜外观正常、声带活动及内收肌力量正常,仅高剂量组24小时见中度至重度急性炎症,无肌肉或黏膜坏死。结论认为即使最大剂量也无显著局部毒性,可考虑I期人体试验。

要点

  • 犬环后杓肌注射长春新碱后约90%药物滞留肌肉,血浆暴露低。
  • 0.6 mg高剂量组仅见暂时性黏膜下炎症,无坏死或功能损害。
  • 结果支持在人体开展I期临床试验评估该治疗策略。

核心结论

  • 犬环后杓肌注射长春新碱即使最大剂量0.6 mg也无显著局部毒性。

研究设计与样本

  • 注射后检测血浆长春新碱浓度,并于24小时(n=7)或14天(n=9)评估声带活动、内收肌功能及组织学。

主要发现

  • 血浆浓度通常在24小时内低于检测限。
  • 所有动物黏膜外观正常、声带活动范围完整、喉内收肌力量正常。
  • 组织学仅高剂量组24小时见黏膜下中度至重度急性炎症,无肌肉或黏膜坏死。

临床怎么用

  • 提示环后杓肌内注射长春新碱局部毒性可接受,可考虑开展I期人体试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: In animal studies, intramuscular vincristine injections have been shown to block reinnervation of the denervated target muscle. This application could be used selectively to influence recovery patterns following injury of recurrent laryngeal nerves (RLNs). However, vincristine is currently Food and Drug Administration approved only for intravenous use. A formal toxicity trial of intramuscular injections was performed. STUDY DESIGN: Animal study. METHODS: Sixteen female canines underwent direct laryngoscopy with injection of moderate- (0.4 mg, n = 8) or high-dose (0.6 mg, n = 8) vincristine into the posterior cricoarytenoid (PCA) muscles. Plasma samples were collected at various time points postinjection and vincristine levels determined. At 24 hours (n = 7) or 14 days (n = 9) postinjection, animals were anesthetized and videolaryngoscopy documented vocal fold mobility and mucosal appearance. Adductor function was measured during stimulation of the RLN. Larynges were processed for histology. RESULTS: Fifteen minutes after injection, plasma vincristine levels averaged 10.2% ± 6.7% of the intravenous maximum, suggesting about 90% of the vincristine remained within the PCA muscle. Plasma levels were usually below detectable limits within 24 hours. At the end points, all animals had grossly normal-appearing mucosa and full range of motion. Laryngeal adductor strength was normal in all cases. Histology showed moderate to severe acute inflammation in the submucosa only in the high-dose group at 24 hours. There was no necrosis of muscle or mucosa. CONCLUSIONS: Intramuscular vincristine injections into the canine PCA muscles resulted in no significant local toxicity, even at the maximum dose. It would be reasonable to evaluate this treatment strategy in a phase I human trial. LEVEL OF EVIDENCE: NA Laryngoscope, 128:E247-E250, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Paniello RC, Bhatt NK, Chernock R, et al. Toxicity trial of canine posterior cricoarytenoid intramuscular vincristine injections. Laryngoscope. 2017. PMID: 29219188. doi:10.1002/lary.26998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。